Introduction
The c-Myc protein, a member of the basic-region-helixloop-helix-leucine zipper (b-HLH-zip) family of transcription factors, is a key regulator of cellular growth and plays a central role in the control of important cellular processes, such as proliferation, differentiation and apoptosis (Adhikary and Eilers, 2005; Cowling and Cole, 2006; Dang et al., 2006; Eilers and Eisenman, 2008) . Deregulated expression of c-Myc or expression of retrovirally encoded versions of the protein (referred to as v-Myc; for review see: Lee and Reddy, 1999) perturbs the balance between these processes and leads to neoplastic transformation of the cells. A large body of evidence has shown that Myc proteins exert their biological effects through activation and repression of specific sets of target genes. Activation of genes by Myc usually requires the binding of Myc, together with its dimerization partner Max, to specific DNA sequences in the promoters of genes to be activated. Cofactor complexes are then recruited by the transactivation domain of Myc, leading to stimulation of promoter activity. How c-Myc and v-Myc suppress the expression of other genes is less well understood, however, accumulating evidence suggests that Myc-mediated repression results from inhibition of other, positively acting transcription factors (Wanzel et al., 2003 , Kleine-Kohlbrecher et al., 2006 . Several transcription factors, including Miz-1, C/EBPb, TFII-I, YY-1, SP1/3, Smad2/3 and NF-Y (Shrivastava et al., 1993; Mink et al., 1996; Gartel et al., 2001; Izumi et al., 2001; Seoane et al., 2001; Staller et al., 2001; Feng et al., 2002 , Herold et al., 2002 have been implicated in the repression of specific genes by Myc.
CCAAT box/enhancer binding proteins (C/EBPs) are basic-region-leucine-zipper transcription factors whose activity is controlled by several different mechanisms, such as alternative translation initiation (Descombes and Schibler, 1991; Calkhoven et al., 2000) , phosphorylation (Nakajima et al., 1993; Trautwein et al., 1993; Buck et al., 1999) , acetylation (Xu et al., 2003; Joo et al., 2004; Cesen˜a et al., 2007) , sumoylation (Eaton and Sealy, 2003) and interaction with specific cofactors (Mink et al., 1997; Kowenz-Leutz and Leutz, 1999) , suggesting that C/EBPs are the key factors in the transcription network whose precise control is crucial for the cell. C/EBPs play central roles in fundamental cellular processes including differentiation, proliferation and growth arrest of specific cell types, including adipocytes, keratinocytes, mammary epithelial cells and myelomonocytic cells (Cao et al., 1991; Yeh et al., 1995; Darlington et al., 1998; Pedersen et al., 2001; Ramji and Foka, 2002; Nerlov, 2007) . In addition to activating specific genes, C/EBPs regulate cellular proliferation through interaction with cell-cycle proteins (Johnson, 2005) . Ectopic C/EBP expression and C/EBP knock-down studies have underscored the critical role of the C/EBPs in differentiating cells (Lin and Lane, 1992; Mu¨ller et al., 1995; Zhang et al., 1997; Tang et al., 2003) . In addition, a large body of evidence suggests that inhibition or deregulation of C/EBP activity contributes to the development of cancer (Pabst et al., 2001; Zahnow et al., 2001; Gombart et al., 2002; Bundy and Sealy, 2003; Nerlov, 2004; Gomis et al., 2006) .
One of the hallmarks of v-Myc and c-Myc is the ability to interfere with differentiation processes, particularly of cells, such as myelomonocytic cells or adipocytes, whose differentiation is dependent on C/EBP factors (Symonds et al., 1986; Hoffman-Liebermann and Liebermann, 1991; Freytag and Geddes, 1992; Heath et al., 2000) . Earlier, we have shown that v-Myc inhibits the transactivation potential of several C/EBP family members (Mink et al., 1996) , suggesting that C/EBPs are crucial targets for Myc in C/EBPdependent differentiation processes. We also reported earlier that the activity of C/EBPb is stimulated by the co-activator p300 and the interaction of C/EBPb and p300 triggers the phosphorylation of the carboxyterminal domain of p300, thereby increasing the activity of p300 as a co-activator of C/EBPb (Schwartz et al., 2003) . We have now explored in more detail how v-Myc inhibits the activity of C/EBPb. We show that the C/EBPb-induced phosphorylation of p300 is mediated by the protein kinase HIPK2 which associates with the C/EBPb-p300 complex. v-Myc interferes with the phosphorylation of p300 by binding itself to the C/EBPb and displacing the kinase from the complex.
Results

v-Myc suppresses the expression of myeloid C/EBPb target genes and interacts with C/EBPb
We have shown before that, v-Myc strongly suppresses the transactivation potential of C/EBPb and thereby down-regulates the expression of C/EBPb target genes in myeloid cells (Mink et al., 1996) . This is illustrated in Figure 1a , where we have compared the expression of the C/EBPb-regulated genes mim-1 and MRP126 in a line of chicken myeloblasts and a subclone of this line that was infected with the v-myc-containing retrovirus MC29. Although, exploring the molecular basis of this inhibitory effect we found that v-Myc and C/EBPb associate with each other. This is shown by the coimmunoprecipitation experiments, using antisera against C/EBPb and v-Myc and extracts of 35 Smethionine-labeled cells that had been transfected with expression vectors for v-Myc and C/EBPb (Figure 1b ). For these and most subsequent experiments, we used a modified form of v-Myc that lacks the gag part of the 110 kd gag-myc fusion protein encoded by MC29. To reduce nonspecific background, each precipitate obtained after immunoprecipitation with antiserum against v-Myc or C/EBPb was dissolved, divided in two aliquots and re-precipitated with anti-Myc or anti-C/EBPb serum. Thus, the first and last lanes of each panel of Figure 1b are input lanes showing the total amounts of v-Myc and C/EBPb, whereas the middle two lanes show the amounts of the co-precipitated proteins. The left panel of Figure 1b shows that a significant amount of v-Myc was co-precipitated with C/EBPb and, conversely, some C/EBPb was co-precipitated with vMyc. It is to be noted that, the same amount of original cell extract was used for all four lanes of this figure, therefore the amount of v-Myc co-precipitated through C/EBPb (visible in the third lane) is directly comparable with the total amount of v-Myc (seen in the first lane). The specificity of the co-precipitation was further assessed by using deletion mutants of C/EBPb. v-Myc did not co-precipitate with the amino terminal C/EBPb deletion mutants DN49 and DN110 (Figure 1b , middle and right panels), indicating that co-precipitation depends on sequences located in the N-terminal domain of C/EBPb. The interaction of v-Myc and C/EBPb was also confirmed in a mammalian two-hybrid experiment using v-Myc/VP16 and Gal4-C/EBPb hybrid proteins (data not shown).
To determine whether v-Myc and C/EBPb also associate in untransfected cells, we carried out sequential co-precipitations using myeloid cells expressing endogenous C/EBPb and the 110 kd gag-myc protein encoded by the MC29 virus. As illustrated in Figure 1c , v-Myc associates also with endogenous C/EBPb. The co-precipitation of proteins in untransfected cells was specific as shown by the control precipitation with nonimmune serum (last two lanes of Figure 1c) . This experiment confirms earlier results obtained with v-Myc transformed quail fibroblasts (Reiter et al., 2007) . S-methionine and subjected to sequential immunoprecipitation as described above. The first immunoprecipitation was additionally carried out with normal rabbit serum (NRS). The black and white arrowheads mark the endogenous C/EBPb and the MC29-encoded p110 gagÀmyc fusion protein, respectively.
v-Myc counteracts the p300-dependent stimulation of the activity of C/EBPb As the transactivation potential of C/EBPb is strongly stimulated by recruitment of the co-activator p300 (Mink et al., 1997) , we were interested to know whether v-Myc disturbs the cooperation of C/EBPb and p300.
To address this possibility, we analysed the expression of the endogenous MRP126 gene in fibroblasts transfected with expression vector for C/EBPb, p300 and vMyc. The chromatin-embedded MRP126 gene is not expressed in fibroblasts but is activated in these cells by ectopic expression of C/EBPb. Moreover, the stimulatory effect of C/EBPb is further increased by expression of p300. The activation of the MRP126 gene has therefore been used as a physiologically relevant readout of C/EBPb activity (Mink et al., 1997) . As shown in Figure 2a , C/EBPb induced the transcription of the MRP126 gene and this was strongly stimulated by p300 (compare lanes 1 and 3 of Figure 2a ). Co-expression of v-Myc reduced the stimulatory effect of p300. v-Myc also inhibited the activation of the MRP126 gene in the absence of co-transfected p300, presumably by interfering with the cooperation of C/EBPb with endogenous p300. The inhibitory effect of v-Myc on the cooperation of C/EBPb and p300 was also confirmed by reporter gene experiments using a C/EBPb-responsive promoter construct (Supplementary Figure 1) . It has been shown earlier that p300 induces the acetylation of C/EBPb which, in turn, stimulates the activity of C/EBPb (Joo et al., 2004; Cesen˜a et al., 2007) . We therefore analysed the p300-dependent acetylation of C/EBPb to further assess the effect of v-Myc on the cooperation of C/EBPb and p300. Figure 2b shows that a protein of the size of C/EBPb was detected with the acetyl-lysine-specific antiserum when p300 was coexpressed with C/EBPb, confirming that p300 induced the acetylation of C/EBPb. The protein recognized by the acetyl-lysine-specific antiserum was absent, when the C/EBPb expression vector was omitted (data not shown), indicating that the acetylated protein was indeed C/EBPb. Interestingly, v-Myc suppressed the p300-dependent acetylation of C/EBPb. To show the specificity of this inhibitory effect, we used the v-Myc mutant DPA which carries a deletion within its amino terminal domain and, as shown before (Mink et al., 1996) , inhibits the activity of C/EBPb only poorly. As shown in Figure 2b , v-Myc-DPA had no significant effect on the acetylation of C/EBPb.
v-Myc inhibits the C/EBPb-dependent phosphorylation of p300
We have shown before that the recruitment of p300 by C/EBPb triggers the phosphorylation of the C-terminal domain of p300, which results in a mobility shift of p300 in SDS-polyacrylamide gels and stimulates the activity of p300 as a co-activator of C/EBPb (Schwartz et al., 2003) . During the course of this work, we noticed that the apparent molecular weight of full-length p300 was slightly lower in the presence of v-Myc than in its absence (see bottom panels in Figure 2a ). This prompted us to investigate whether v-Myc interferes with the C/EBPb-induced phosphorylation of p300. Figure 3a shows that the mobility shift of full-length p300 which was induced by co-expression of C/EBPb was suppressed by v-Myc. To show the specificity of this inhibitory effect, we used the v-Myc mutant DPA which carries a deletion within its amino terminal domain and, as shown before (Mink et al., 1996) , inhibits the activity of C/EBPb only poorly. Consistent with this, v-Myc-DPA did not show significant inhibition of the C/EBPbinduced mobility shift. As the C/EBPb-induced mobility shift is rather small in the context of full-length p300, we also co-expressed C/EBPb with the C-terminal domain of p300 (p300/1751-2370) to better visualize the effect of v-Myc on the phosphorylation of this domain. Consistent with earlier work (Schwartz et al., 2003) C/EBPb induced the appearance of multiple slow-migrating forms of p300/1751-2370 (Figure 3b ). Phosphatasetreatment experiments have shown before that the slower-migrating bands of p300/1751-2370 and of fulllength p300 correspond to phosphorylated forms of the protein (Schwartz et al., 2003) . In the presence of v-Myc, the slow-migrating forms of p300/1751-2370 became less prominent, confirming that v-Myc interferes with the phosphorylation of p300, whereas v-Myc-DPA exerted only a minor effect on the C/EBPb-induced mobility shift. Taken together, these experiments suggested that v-Myc suppresses the C/EBPb-induced phosphorylation of C-terminal residues of p300.
We have earlier identified serine 2280 of p300 as one of several aminoacid residues whose phosphorylation is induced by C/EBPb (Schwartz et al., 2003) . To be able to monitor C/EBPb-induced phosphorylation of p300 independently of a mobility shift, we raised a phosphospecific antiserum against Ser-2280 of p300. The antiserum did not detect p300/1751-2370 in the absence of C/EBPb but reacted strongly with the slowest-migrating (a) QT6 cells were transfected with expression vectors for C/EBPb, p300, v-Myc and v-Myc-DPA. Polyadenylated RNA was analysed by northern blotting with probes specific for the chicken MRP126 and GAPDH genes (top). In addition, total cell extracts were analysed by western blotting using HA-and C/EBPb-specific antibodies (bottom). (b) QT6 cells were transfected with expression vectors for HA-tagged full-length p300, C/EBPb, v-Myc or v-Myc DPA, as indicated at the bottom. Total cell extracts were analysed by western blotting with antibodies against C/EBPb (top), acetylated lysine (middle) or Myc (bottom).
form of p300/1751-2370 appearing in the presence of C/EBPb. Moreover, the S2280A mutant of p300/ 1751-2370 did not react with the phospho-specific antiserum (supplementary Figure 2) . This showed the specificity of the antiserum and confirmed that C/EBPb triggers the phosphorylation of Ser-2280. Figure 3c shows that v-Myc clearly diminished the C/EBPbinduced phosphorylation of Ser-2280, whereas v-Myc-DPA had no significant effect, again showing that v-Myc suppresses the C/EBPb-induced phosphorylation of p300.
To show the suppressive effect of v-Myc on the phosphorylation of p300 in a more physiological setting, we made use of the 3T3-L1 pre-adipocyte cell-line. 3T3-L1 cells have been instrumental in showing an inhibitory effect of Myc on the adipocyte differentiation program (Freytag and Geddes, 1992; Heath et al., 2000) . After induction of differentiation, C/EBPb is initially upregulated and activates further genes, such as C/EBPa and PPARg which then give rise to the adipocyte phenotype (Lane et al., 1999; Otto and Lane, 2005) . Myc has been shown to interfere with the downstream effects of C/EBPb (Freytag and Geddes, 1992; Heath et al., 2000) , suggesting that C/EBPb is a key target of Myc in the suppression of adipocyte differentiation. The 3T3-L1 cell line, therefore, seemed to be a suitable model to study the effect of Myc on the phosphorylation of p300 in a physiological context. We used earlier characterized subclones of 3T3-L1 cells that had been stably transfected with an expression vector for chicken c-Myc or with a control vector (Heath et al., 2000) . Figure 3d shows that the control cells differentiated into adipocytes as evidenced by the accumulation of lipid droplets in their cytoplasm, whereas the c-Myc expressing cells failed to differentiate. We then asked whether the inhibition of adipocyte differentiation by Myc was accompanied by an alteration of the mobility of p300. It is interesting that, a slower migrating form of p300 appeared after induction of differentiation in the control cells, whereas this did not happen in the Myc expressing cells (Figure 3e ). We then used the phospho-specific antiserum to examine the effect of Myc on the phosphorylation of Ser-2280 of endogenous p300 in the 3T3-L1 cells. After induction of differentiation, the phosphorylation of Ser-2280 was increased in the control cells but remained low in the Myc-expressing cells (Figure 3e) , confirming that the phosphorylation of p300 at Ser-2280 increases during adipocyte differentiation and that this is prevented by Myc. Together, these data are consistent with the notion that Myc suppresses the C/EBPb-induced phosphorylation of endogenous p300 also in a physiological context. Protein kinase HIPK2 mediates C/EBPb-induced phosphorylation of p300 Aikawa et al. (2006) have shown recently that AML1, like C/EBPb, induces the phosphorylation of p300 and that the AML1-induced phosphorylation of p300 is mediated by the protein kinase HIPK2. This prompted us to investigate whether HIPK2 is also involved in the phosphorylation of p300/1751-2370 induced by C/ EBPb. In the absence of C/EBPb, expression of HIPK2 had only a very slight effect on the mobility of p300/ 1751-2370, however, in the presence of a small amount of C/EBPb HIPK2 induced a very strong mobility shift (Figure 4a ), indicating that C/EBPb and HIPK2 cooperate to induce phosphorylation of p300/1751-2370. By contrast, expression of a kinase-dead mutant of HIPK2 diminished the mobility shift induced by C/ EBPb (compare lanes 5 and 6 of Figure 4a ). We also used the antiserum against phosphorylated Ser-2280 to show that HIPK2 strongly induces the phosphorylation of this site (Figure 4b ).
To gather additional support for the notion that HIPK2 is responsible for the C/EBPb-induced phos- Figure 4 Protein kinase HIPK2 mediates C/EBPb-dependent phosphorylation of p300. (a) QT6 cells were transfected with expression vectors for C/EBPb, p300/1751-2370 and HA-tagged wild-type or kinase-dead mutant HIPK2. Numbers refer to DNA amounts (in ng). Cell extracts were analysed by western blotting with the indicated antibodies. (b) QT6 cells were transfected with expression vectors for C/EBPb and HA-tagged HIPK2 and p300/1751-2370. Cell extracts were analysed by western blotting using antibodies against p300 or phospho-p300 (Ser2280). Black and white arrows in A and B mark unphosphorylated or highly phosphorylated forms of p300/1751-2370, respectively. (c) Hela cells were transfected with expression vectors for C/EBPb and p300/1751-2370. In addition, an expression vector for HIPK2-specific shRNA (pSuper-HIPK2) or a control vector (pSuper) was included, as indicted below the lanes (numbers refer to mg amounts). Cell extracts were analysed by western blotting with the indicated antibodies. (d) 3T3-L1 HIPK2 knock-out and control cells were analysed by western blotting with antibodies against p300, phospho-p300 (Ser-2280), HIPK2 and bactin. Cells were harvested before (À lanes) or after 2 days of differentiation ( þ lanes). Figure 5 v-Myc displaces HIPK2 from the C/EBPb-p300 complex. (a) QT6 cells were transfected with the expression vectors for Flagtagged C/EBPb, p300/1751-2370 and HA-tagged kinase-dead HIPK2. Total cell extracts (TCE) were analysed by western blotting using HA-, p300-or C/EBPb-specific antibodies (as indicated on the right). In addition, cell extracts were first immunoprecipitated with antibodies against the Flag-tag, followed by western blotting using HA-, p300-or C/EBPb-specific antibodies. All lanes of panel A are derived from the same gel. (b) Total extracts from cells transfected with expression vector for kinase-dead HIPK2 ( þ ) or from untransfected cells (À) were incubated with glutathione-sepharose beads loaded with equal amounts of glutathione-S-transferase (GST) or a GST-C/EBPb fusion protein, as indicated. Bound proteins and aliquots of the cell extract (input lanes) were analysed by western blotting using anti-HA antibodies. (c) QT6 cells were transfected with the indicated expression vectors. Aliquots of the total cell extracts (TCE) were analysed by western blotting using the indicated antibodies. In addition, cell extracts were immunoprecipitated with Flag antibodies, followed by SDS-PAGE and western blotting with HA-specific antibodies (second panel from top). The black arrow on the left side marks the co-precipitated HIPK2. (d and e) The aminoacid sequences of part of the N-terminal region of chicken, human and mouse C/EBPb and the amino acids that have been altered in the FYY/AAA mutant of C/EBPb are shown in the single letter amino acid code at the top. The QT6 cells were transfected with expression vectors for HA-tagged v-Myc (d) or HA-tagged HIPK2 (e) and wild-type C/EBPb or the FYY/AAA mutant of C/EBPb, as indicated. Cell extracts (TCE) were analysed by western blotting using HA-and C/ EBPb-specific antibodies or were first immunoprecipitated with antibodies against the C/EBPb, followed by western blotting using HAspecific antibodies, as indicated on the right side.
phorylation of p300, we transiently transfected expression vectors for C/EBPb, p300/1751-2370, HIPK2-specific shRNA or the corresponding control vector into Hela cells and analysed the phosphorylation of p300 at Ser-2280 by western blotting (Figure 4c ). This experiment clearly showed that the Ser-2280 phosphorylation, which was induced by C/EBPb, was diminished by HIPK2-specific shRNA, indicating that endogenous HIPK2 is responsible for the phosphorylation of p300. The fact that the HIPK2-specific shRNA was effective in reducing HIPK2 expression was confirmed by a control experiment using an expression vector for HIPK2 (Supplementary Figure 3) . These data, therefore, identify HIPK2 as the protein kinase that cooperates with C/EBPb in the phosphorylation of p300. Myc inhibition of C/EBPb S Steinmann et al
To substantiate this conclusion in a more physiological setting, we generated a stable HIPK2 knock-down clone of the 3T3-L1 cell line. Western blot analysis of the cells before or after induction of differentiation (Figure 4d ) confirmed the knock-down of endogenous HIPK2. In accordance with the data shown in Figure 3e , the appearance of a retarded form of p300 and the phosphorylation of Ser-2280 was increased after the induction of differentiation. It is to be noted that, this increase was diminished in the knock-down cells when compared with the control cells. Taken together, this confirms that, endogenous HIPK2 is required for p300 phosphorylation in a physiological C/EBPb-dependent process.
v-Myc prevents C/EBPb-induced phosphorylation of p300 by displacing HIPK2 from the C/EBPb-p300 complex Finally, we explored the mechanism by which v-Myc affects phosphorylation of p300. We first asked whether HIPK2 could be co-precipitated with the C/EBPb-p300 complex. We analysed extracts from cells transfected with expression vectors for C/EBPb, p300/1751-2370 and the kinase-dead mutant of HIPK2 by immunoprecipitation with antibodies against C/EBPb. We used the kinase-dead mutant rather than the wild-type version of HIPK2 because the mutant HIPK2 does not undergo autophosphorylation and migrates as a sharper band in the SDSpolyacrylamide gel which facilitates its detection in the co-precipitate. As shown in Figure 5a , HIPK2 was clearly co-precipitated with the C/EBPb-p300 complex (lane 3). Interestingly, HIPK2 was also co-precipitated through C/EBPb in the absence of exogenous p300 (compare lanes 2 and 3 of Figure 5a ). Similar results were also obtained for wild-type HIPK2 (data not shown). We also confirmed that HIPK2 and C/EBPb interact in vitro, as shown by the GST pull-down assay in Figure 5b . Unfortunately, despite numerous attempts using our own HIPK2-specific antiserum as well as several commercially available Antisera, the low-expression level of Hipk2, and the limited sensitivity of the antisera have prevented us from showing the interaction of C/EBPb and HIPK2 on the level of endogenous proteins. Nevertheless, the HIPK2 knock-down experiments described above provide sufficient evidence to conclude that HIPK2 mediates C/EBPb-induced phosphorylation of p300.
Finally, we asked whether v-Myc affects the association of HIPK2 with the C/EBPb-p300 complex. Figure 5c shows that increasing amounts of v-Myc (lanes 1 and 2) but not of v-Myc-DPA (lanes 3 and 4) caused a reduction of the amount of HIPK2 coprecipitating with C/EBPb. Thus, it seems that v-Myc interferes with the C/EBPb-HIPK2 interaction.
The data shown in Figure 1b had suggested that the first 49 amino acids of C/EBPb are responsible for its interaction with v-Myc. A central part of this sequence (from amino acids 22-35) is highly conserved between several vertebrate C/EBPb homologs (see top of Figure 5d ). To observe if this part of C/EBPb is involved in the interaction with v-Myc we mutated several of the highly conserved residues and compared the ability of wild-type and mutated C/EBPb to interact with v-Myc. Interestingly, the mutation decreased the ability of C/EBPb to co-precipitate v-Myc, indicating that the conserved sequence is involved in binding vMyc. We then asked whether the mutated C/EBPb was still able to co-precipitate HIPK2. It is to be noted that, the interaction between C/EBPb and HIPK2 was also affected by the mutation, suggesting that Myc and HIPK2 bind to the same or closely spaced binding sites in the N-terminal part of C/EBPb (Figure 5e ). Taken together, our data suggest that v-Myc suppresses HIPK2-mediated phosphorylation of p300 by displacing HIPK2 from C/EBPb, possibly because v-Myc and HIPK2 share the same or closely spaced binding sites in the N-terminal domain of C/EBPb.
Discussion
Our work provides new insight into two aspects of the cooperation of C/EBPb with the co-activator p300. Firstly, we have identified the protein kinase HIPK2 as a new player which is involved in the crosstalk between C/EBPb and p300. Secondly, our work shows a new mechanism of transcriptional repression by v-Myc.
We have shown earlier that the recruitment of p300 by C/EBPb triggers the phosphorylation of multiple sites in the C-terminal domain of p300. We have referred to this mechanism of C/EBPb-induced phosphorylation of p300 as 'activation on demand' because we showed that the phosphorylation of p300 increases its activity as a co-activator of C/EBPb (Schwartz et al., 2003) . This suggested that the phosphorylation might act as a regulatory mechanism that specifically modulates the activity only of the fraction of p300 that is recruited by C/EBPb or by certain other transcription factors (such as other C/EBP family members, c-Jun or AML1) that trigger similar phosphorylation events (Schwartz et al., 2003; Aikawa et al., 2006) . By using a variety of assays, including the expression of active or catalyticallyinactive forms of HIPK2 and siRNA-mediated silencing of endogenous HIPK2, we have now shown that the protein kinase HIPK2 is involved in the C/EBPbinduced phosphorylation of p300. Our work also shows that HIPK2-mediated phosphorylation of p300 is important for C/EBPb activity, as shown by the inhibitory effect of a dominant-negative mutant of HIPK2 on the C/EBPb-dependent activation of an endogenous, chromatin embedded C/EBPb target gene and by the suppression of the C/EBPb-dependent adipocyte differentiation program after the knock-down of HIPK2. Our finding that HIPK2 interacts with C/EBPb provides a plausible explanation for the observation that the recruitment by C/EBPb triggers the phosphorylation of p300. p300 molecules that are bound to C/EBPb might be phosphorylated preferentially because they are in close proximity to the kinase, whereas free p300 will be phosphorylated less efficiently or not at all. Aikawa et al. (2006) have reported that HIPK2 also interacts with p300; additional effects, such as conformational changes of p300 or the kinase that are induced by the interaction with C/EBPb could therefore also play a role in the stimulation of the phosphorylation of p300 by C/EBPb. The observation that HIPK2 binds to C/EBPb and induces the phosphorylation of p300 in vivo strongly suggests that HIPK2 directly phosphorylates p300. Nevertheless, as we have not yet carried out in vitro phosphorylation experiments using purified HIPK2, we cannot completely exclude the possibility that another protein kinase which acts downstream of HIPK2 is involved in the phosphorylation of p300.
HIPK2 is a multifunctional protein kinase which is engaged in a variety of activities, including transcriptional repression, developmental processes and the DNA-damage response (reviewed in Rinaldo et al., 2007) . Our work adds a new aspect to this picture of HIPK2 activities by showing that HIPK2 plays a role in C/EBPb-dependent gene activation. Preliminary data suggest that the knock-down of HIPK2 also interferes with adipocyte differentiation (unpublished results). A large body of work has implicated C/EBPb as an important player in a variety of differentiation processes, including the differentiation of adipocytes, keratinocytes, mammary epithelial cells and myelomonocytic cells (Cao et al., 1991; Yeh et al., 1995; Darlington et al., 1998; Pedersen et al., 2001; Ramji and Foka, 2002; Nerlov, 2007) . HIPK2 might therefore play a more general role in C/EBPb-dependent differentiation processes.
The second major aspect of our work addresses the mechanism by which v-Myc interferes with the expression of C/EBPb regulated genes. It is well known that v-Myc, and c-Myc, exert their biological functions not only by activating, but also by down-regulating the expression of specific sets of genes. We have shown earlier that v-Myc suppresses the activity of C/EBPb and down-regulates C/EBPb target genes in myelomonocytic cells (Mink et al., 1996) . The work described here shows that v-Myc interacts with C/EBPb, thereby confirming and extending earlier work which showed coprecipitation of Myc and C/EBPb from cell extracts (Tinel et al., 2003; Reiter et al., 2007) . Furthermore, our work suggests that v-Myc inhibits C/EBPb activity by perturbing the cooperation of C/EBPb and p300. This was shown by the suppressive effects of v-Myc on the p300-dependent stimulation of C/EBPb activity, the C/ EBPb-induced phosphorylation of p300, and the p300-dependent acetylation of C/EBPb. As the phosphorylation of p300 by HIPK2 has been shown to increase the acetyl-transferase activity of the co-activator (Aikawa et al., 2006) , the suppression of p300-dependent acetylation of C/EBPb by v-Myc might be a direct consequence of the diminished phosphorylation of p300. As acetylation of C/EBPb, in turn, increases its transactivation potential (Joo et al., 2004; Cesen˜a et al., 2007) , this might provide an overall explanation for the inhibitory effect of v-Myc on C/EBPb activity.
Our work also suggests a mechanistic explanation for how v-Myc suppresses the C/EBPb-induced phosphorylation of p300: All of our results are consistent with a model in which v-Myc interacts with the aminoterminal part of C/EBPb at a site adjacent to or overlapping with the binding region for HIPK2, thereby preventing the binding of HIPK2 to C/EBPb and, as a consequence, the phosphorylation of C/EBPb-bound p300.
Although our earlier work showed that c-Myc was also able to suppress C/EBP transactivation activity (Mink et al., 1996) we have not yet analysed in detail whether v-Myc and c-Myc act in the same manner to inhibit the activity of C/EBPb. Our observation that the phosphorylation of p300 increases during adipocyte differentiation and that this increase is blocked by c-Myc (Figure 4) at least raises the possibility that the new inhibitory mechanism described here might also be involved in the suppression of the downstream targets of C/EBPb by c-Myc.
In summary, our work has shown for the first time a link between the phosphorylation of p300, protein kinase HIPK2 and the inhibitory activity of v-Myc. Together with earlier work, which has implicated p300 as a target of c-Myc in the suppression of Miz-1 activity Staller et al., 2001 , Herold et al., 2002 , our work emphasizes the role of p300 as an important mediator of the inhibitory effects of Myc on gene expression. Finally, our results show that the C/EBPb-induced phosphorylation of p300 is used as a regulatory mechanism to modulate the activity of C/EBPb.
Materials and methods
Cells
QT6 is a line of quail fibroblasts and HD11 cells are MC29-transformed chicken macrophages. BM2 is a line of AMVtransformed chicken myeloblasts. BM2(MC29) are BM2 cells infected with MC29 virus (Mink et al., 1996) . Subclones of the mouse 3T3-L1 stably transfected with a c-Myc expression vector or the corresponding empty expression vector were obtained from D Crouch (Heath et al., 2000) .
Expression vectors
Expression vector for full-length p300 (pCMV-p300CHA) was obtained from R Eckner (Eckner et al., 1994) . Expression vectors for truncated forms of p300 (p300/1751-2370 and p300/1515-1998) and full-length chicken C/EBPb have been described (Mink et al., 1997) . pCRNC-CCRDN49 and pCRNC-CCRDN110 encode deletion mutants of C/EBPb lacking 49 or 110 aminoacids from the N-terminus, respectively. pCDNA3-C/EBPb-mut1 encodes a mutant of fulllength C/EBPb in which amino acids F27, Y28 and Y28 are replaced by alanine. Expression vectors for full-length v-Myc (pCDNA3-wtMyc) and the deletion mutant Myc-DPA (pCDNA3-Myc-DPA) have been described (Mink et al., 1996) . In the mutant DPA, v-Myc amino acids 45-148 are missing. Expression vectors for HA-tagged wild-type or kinase-dead HIPK2 were obtained from T Hoffmann.
